Results 161 to 170 of about 3,168 (197)
Some of the next articles are maybe not open access.
Nonresponder Considerations for Romosozumab Treatment
Calcified Tissue International, 2023Romosozumab can increase bone mineral density (BMD) in patients with osteoporosis, but some patients do not respond to it. This study aimed to identify risk factors for being a nonresponder to romosozumab treatment. This retrospective observational study included 92 patients.
Ayako Tominaga +7 more
openaire +2 more sources
Romosozumab: A Review in Postmenopausal Osteoporosis
Drugs & Aging, 2020Romosozumab (Evenity®), a humanized monoclonal antibody, promotes bone formation and inhibits bone resorption by inhibiting sclerostin, a protein involved in the regulation of bone formation. Subcutaneous romosozumab is approved in several countries, including those of the EU for treating severe osteoporosis as well as in the USA for osteoporosis in ...
Julia, Paik, Lesley J, Scott
openaire +2 more sources
Romosozumab/CDP7851 for the treatment of osteoporosis
Expert Review of Endocrinology & Metabolism, 2015Osteoporosis is an important worldwide health problem, conferring significant costs on healthcare. Current osteoporosis therapies are anti-resorptive and have proven anti-fracture efficacy, while there is a paucity of osteoanabolic therapies. Romosozumab is a humanized monoclonal antibody against sclerostin, an inhibitor of osteoblastic activity.
Ie-Wen, Sim, Peter R, Ebeling
openaire +2 more sources
Romosozumab — Promising or Practice Changing?
New England Journal of Medicine, 2017Over the past decade, the osteoporosis landscape has changed. Even though more treatment options are available, fewer measurements of bone mass are being performed and fewer prescriptions for antiosteoporosis agents are being written — the last probably related to concerns about known side effects of bisphosphonates, such as atypical femoral fractures ...
openaire +2 more sources
Romosozumab: First Global Approval
Drugs, 2019Romosozumab (EVENITY™) is a humanised monoclonal antibody against sclerostin being developed by Amgen and UCB for the treatment of osteoporosis. On the basis of favourable results from several phase III trials in postmenopausal women with osteoporosis, and a single trial in men with osteoporosis, romosozumab is being considered for marketing approval ...
openaire +2 more sources
Sequential and combination therapy with romosozumab
Journal of Bone and Mineral MetabolismThe introduction of the bone-forming agent romosozumab has led to a dramatic improvement in osteoporosis treatment. While bisphosphonates remain the most commonly used drugs for the treatment of osteoporosis, it is recommended that patients at high risk of fractures initially receive bone-forming agents, followed by sequential treatment with bone ...
openaire +2 more sources